BRENDA - Enzyme Database show
show all sequences of 1.14.14.55

CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population

Mirghani, R.A.; Sayi, J.; Aklillu, E.; Allqvist, A.; Jande, M.; Wennerholm, A.; Eriksen, J.; Herben, V.M.; Jones, B.C.; Gustafsson, L.L.; Bertilsson, L.; Pharmacogenet. Genomics 16, 637-645 (2006)

Data extracted from this reference:

Cloned(Commentary)
Commentary
Organism
genes CYP3A5 and CYP3A4, DNA sequence determination, genotyping of two different human populations revealing the CYP3A5 and the CYP3A4 genotypes
Homo sapiens
Engineering
Amino acid exchange
Commentary
Organism
A6986AG
single nucleotide polymorphism responsible for different CYP3A genotypes, CYP3A5 allele and genotype frequency in the populations, overview
Homo sapiens
additional information
the CYP3A5 genotype has significant effect on quinine 3-hydroxylation in black Tanzanians, who have lower total CYP3A activity compared to a population of Swedish caucasians, overview
Homo sapiens
Natural Substrates/ Products (Substrates)
Natural Substrates
Organism
Commentary (Nat. Sub.)
Natural Products
Commentary (Nat. Pro.)
Organism (Nat. Pro.)
Reversibility
quinine + NADPH + O2
Homo sapiens
quinine is used for treatment of severe forms of Plasmodium falciparum malaria, phenotyping of two different populations, overview
3-hydroxyquinine + NADP+ + H2O
-
-
?
Organism
Organism
Primary Accession No. (UniProt)
Commentary
Textmining
Homo sapiens
-
-
-
Substrates and Products (Substrate)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
quinine + NADPH + O2
-
676312
Homo sapiens
3-hydroxyquinine + NADP+ + H2O
-
-
-
?
quinine + NADPH + O2
quinine is used for treatment of severe forms of Plasmodium falciparum malaria, phenotyping of two different populations, overview
676312
Homo sapiens
3-hydroxyquinine + NADP+ + H2O
-
-
-
?
Cofactor
Cofactor
Commentary
Organism
Structure
NADPH
-
Homo sapiens
Cloned(Commentary) (protein specific)
Commentary
Organism
genes CYP3A5 and CYP3A4, DNA sequence determination, genotyping of two different human populations revealing the CYP3A5 and the CYP3A4 genotypes
Homo sapiens
Cofactor (protein specific)
Cofactor
Commentary
Organism
Structure
NADPH
-
Homo sapiens
Engineering (protein specific)
Amino acid exchange
Commentary
Organism
A6986AG
single nucleotide polymorphism responsible for different CYP3A genotypes, CYP3A5 allele and genotype frequency in the populations, overview
Homo sapiens
additional information
the CYP3A5 genotype has significant effect on quinine 3-hydroxylation in black Tanzanians, who have lower total CYP3A activity compared to a population of Swedish caucasians, overview
Homo sapiens
Natural Substrates/ Products (Substrates) (protein specific)
Natural Substrates
Organism
Commentary (Nat. Sub.)
Natural Products
Commentary (Nat. Pro.)
Organism (Nat. Pro.)
Reversibility
quinine + NADPH + O2
Homo sapiens
quinine is used for treatment of severe forms of Plasmodium falciparum malaria, phenotyping of two different populations, overview
3-hydroxyquinine + NADP+ + H2O
-
-
?
Substrates and Products (Substrate) (protein specific)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
quinine + NADPH + O2
-
676312
Homo sapiens
3-hydroxyquinine + NADP+ + H2O
-
-
-
?
quinine + NADPH + O2
quinine is used for treatment of severe forms of Plasmodium falciparum malaria, phenotyping of two different populations, overview
676312
Homo sapiens
3-hydroxyquinine + NADP+ + H2O
-
-
-
?
Other publictions for EC 1.14.14.55
No.
1st author
Pub Med
title
organims
journal
volume
pages
year
Activating Compound
Application
Cloned(Commentary)
Crystallization (Commentary)
Engineering
General Stability
Inhibitors
KM Value [mM]
Localization
Metals/Ions
Molecular Weight [Da]
Natural Substrates/ Products (Substrates)
Organic Solvent Stability
Organism
Oxidation Stability
Posttranslational Modification
Purification (Commentary)
Reaction
Renatured (Commentary)
Source Tissue
Specific Activity [micromol/min/mg]
Storage Stability
Substrates and Products (Substrate)
Subunits
Temperature Optimum [C]
Temperature Range [C]
Temperature Stability [C]
Turnover Number [1/s]
pH Optimum
pH Range
pH Stability
Cofactor
Ki Value [mM]
pI Value
IC50 Value
Activating Compound (protein specific)
Application (protein specific)
Cloned(Commentary) (protein specific)
Cofactor (protein specific)
Crystallization (Commentary) (protein specific)
Engineering (protein specific)
General Stability (protein specific)
IC50 Value (protein specific)
Inhibitors (protein specific)
Ki Value [mM] (protein specific)
KM Value [mM] (protein specific)
Localization (protein specific)
Metals/Ions (protein specific)
Molecular Weight [Da] (protein specific)
Natural Substrates/ Products (Substrates) (protein specific)
Organic Solvent Stability (protein specific)
Oxidation Stability (protein specific)
Posttranslational Modification (protein specific)
Purification (Commentary) (protein specific)
Renatured (Commentary) (protein specific)
Source Tissue (protein specific)
Specific Activity [micromol/min/mg] (protein specific)
Storage Stability (protein specific)
Substrates and Products (Substrate) (protein specific)
Subunits (protein specific)
Temperature Optimum [C] (protein specific)
Temperature Range [C] (protein specific)
Temperature Stability [C] (protein specific)
Turnover Number [1/s] (protein specific)
pH Optimum (protein specific)
pH Range (protein specific)
pH Stability (protein specific)
pI Value (protein specific)
Expression
General Information
General Information (protein specific)
Expression (protein specific)
KCat/KM [mM/s]
KCat/KM [mM/s] (protein specific)
745448
Igbinoba
Influence of a Nigerian honey ...
Homo sapiens
J. Clin. Pharm. Ther.
40
545-549
2015
-
-
-
-
-
-
1
-
-
-
-
1
-
2
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
703423
Wanwimolruk
Variable inhibitory effect of ...
Homo sapiens
Drug Metabol. Drug Interact.
24
17-35
2009
1
1
-
-
-
-
3
-
1
-
-
-
-
6
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
1
1
-
1
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
706089
Diczfalusy
4Beta-hydroxycholesterol is a ...
Homo sapiens
Pharmacogenet. Genomics
18
201-208
2008
-
1
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
-
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
1
1
-
-
-
686501
Allqvist
Inhibition of CYP3A4 and CYP3A ...
Homo sapiens
Eur. J. Clin. Pharmacol.
63
173-179
2007
-
-
-
-
-
-
5
1
1
-
-
1
-
2
-
-
1
-
-
1
-
-
1
-
1
-
-
-
1
-
-
1
-
-
5
-
-
-
1
-
-
-
5
5
-
1
1
-
-
1
-
-
-
1
-
1
-
-
1
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
676312
Mirghani
CYP3A5 genotype has significan ...
Homo sapiens
Pharmacogenet. Genomics
16
637-645
2006
-
-
1
-
2
-
-
-
-
-
-
1
-
1
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
1
-
-
-
-
-
1
1
-
2
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744749
Numata
Ontogeny of hepatic microsoma ...
Pygoscelis adeliae
Comp. Biochem. Physiol. C
138
53-58
2004
-
-
-
-
-
-
3
-
1
-
-
1
-
3
-
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
1
-
-
1
-
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744838
Mirghani
Quinine 3-hydroxylation as a ...
Homo sapiens
Eur. J. Clin. Pharmacol.
59
23-28
2003
-
-
-
-
-
-
1
-
-
-
-
1
-
2
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744611
Wanwimolruk
Is quinine a suitable probe t ...
Homo sapiens
Br. J. Clin. Pharmacol.
54
643-651
2002
-
-
-
-
-
-
1
-
-
-
-
1
-
1
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744769
Mirghani
Enzyme kinetics for the forma ...
Homo sapiens
Drug Metab. Dispos.
30
1368-1371
2002
-
-
-
-
-
-
3
-
1
-
-
1
-
2
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
1
-
-
1
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744743
Mirghani
The roles of cytochrome P450 ...
Homo sapiens
Clin. Pharmacol. Ther.
66
454-460
1999
-
-
-
-
-
-
2
-
-
-
-
1
-
1
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
1
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
285328
Zhao
Mutual inhibition between quin ...
Homo sapiens
Drug Metab. Dispos.
26
188-191
1997
-
-
-
-
-
-
4
-
1
-
-
-
-
2
-
-
-
-
-
1
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
1
-
-
-
-
-
-
-
-
1
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
285329
Zhao
The in vitro hepatic metabolis ...
Canis lupus familiaris, Homo sapiens, Mus musculus, Rattus norvegicus
J. Pharmacol. Exp. Ther.
283
1168-1176
1997
4
-
-
-
-
-
32
4
4
-
-
-
-
10
-
-
-
-
-
4
-
-
4
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
-
-
-
-
-
32
-
4
4
-
-
-
-
-
-
-
-
4
-
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744608
Zhang
Evidence for involvement of h ...
Homo sapiens
Br. J. Clin. Pharmacol.
43
245-252
1997
1
-
-
-
-
-
4
1
1
-
-
1
-
2
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
4
1
1
1
-
-
1
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744609
Zhao
Metabolic interactions of sel ...
Homo sapiens
Br. J. Clin. Pharmacol.
44
505-511
1997
1
-
-
-
-
-
14
-
1
-
-
1
-
1
-
-
-
-
-
1
-
-
2
-
-
-
-
-
-
-
-
-
-
-
13
1
-
-
-
-
-
-
13
14
-
-
1
-
-
1
-
-
-
-
-
1
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
285327
Zhao
Identification of human cytoch ...
Homo sapiens
J. Pharmacol. Exp. Ther.
279
1327-1334
1996
-
-
1
-
-
-
5
3
1
-
-
-
-
2
-
-
-
-
-
1
-
-
1
-
-
-
-
2
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
5
-
3
1
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
285330
Relling
Human cytochrome P450 metaboli ...
Homo sapiens
J. Pharmacol. Exp. Ther.
261
491-496
1992
-
-
-
-
-
-
-
2
1
-
-
-
-
1
-
-
-
-
-
1
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
1
-
-
-
-
-
-
-
-
1
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-